Issuu on Google+

Relevant Stage 4 Cancer Solutions

As technology and our knowledge base continues to grow, it becomes more important than ever to learn what is present in the realm of modern-day cancer treatments – in particular, the availability of new techniques to deal with advanced and stage 4 cancer. An article on the United States’ website explains, "Nearly one out of two Americans born today will be diagnosed with cancer at some point in their lifetime." Moreover, “About 1,596,670 new cancer cases are expected to be diagnosed in 2011 about 571,950 Americans are expected to die of cancer, more than 1,500 people a day – and cancer is the second most common cause of death in the US, exceeded only by heart disease. In the US, cancer alone accounts for nearly 1 of every 4 deaths," reports the *American Cancer Society. Amid these turbulent seas, there is a powerful treatment with which to approach stage 4 cancer called anti-angiogenic therapy. It works by starving the cancer cells from nutrients, thereby impeding its growth and spread. It is reported that nearly 90 percent of cancer patients succumb when their cancer metastasizes – the calling card of stage 4 cancer. Angiogenesis is the process by which tumors grow by attracting blood vessels to “nourish” themselves. However, a technique exists to thwart these very processes. With newly developed modern

“alternative” medicines, both metastasis and angiogenesis can be impeded or even subjugated. Envita leads the domestic pack by currently offering such integrative and unique processes. There is no denying that patients benefit from an anti-angiogenic approach to supplement most traditional chemotherapy regimes. Through rigorous tests and analysis, Envita recommends and implements strategies that will work synergistically with the body to enhance the ultimate goal of patient health and well-being. With these great developments, it is important to give credit where credit is due. The origin of this research field began with Judah Folkman, who realized that a tumor placed in a lab container had only a limited potential for growth, establishing that its micro vascular network was being disrupted. In the early days of his papers, 1964 to 1989, his findings were largely overlooked by many. While they agreed that there was evidence of newly forming vessels, the assumption was that the smaller, weaker cell networks were merely a side effect associated with the dying tumor cells. Eventually, Folkman could prove that the new vessels were actually being fashioned by the cancer cells themselves as a means of supplemental nourishment. In hindsight, it is something of an embarrassment that Dr. Folkman was treated the way he was in the early days of his findings. In an industry so overcome by a poor trackrecord, one would think that innovators, free thinkers, and pioneers would be eagerly welcomed to the table. Unfortunately, cancer research, like so many other fields, seems to harbor the same common pattern of contempt for the new and unknown. Another such example of this contemptuous foolery came when Don Ingber found that a fungus contaminated some of his endothelial cell test samples, which caused their growth to cease. Of course, Inber was ignored and treated like a quack, until later it was proven that angiogenesis could, in fact, be inhibited. Today, anti-angiogenic drugs such as sorafenib (Nexavar®), sunitinib (Sutent®), pazopanib (Votrient®), and everolimus (Afinitor®) are typically prescribed in late-stage cancers in order to impeded growth. That being said, a simple agent like oxygen (not patentable) is an oft overlooked. To put it mildly, oxygen is nothing less than a dominant anti-angiogenic agent. Oxygen becomes an important agent for stage 4 cancer treatment. In fact, errors occurring in oxygen metabolism are often at the root of cancer causes as well as their continued development. Moreover, understanding the role of oxygen and correctly administering it can be vital for success in stage 4 cancer cases.

It is no secret that cancer cells rely upon a blood supply to spread. So, it stands to reason that angiogenesis should be blocked to stop tumor growth. Virtually, all tumors demand an unending supply of nutrients supplied via blood to continue to spread. Without such supplies, tumor growth is limited to a manageable 2 mm. In stage 4 cancer cases, it is a lack of oxygen that ultimately feeds growth and spread. The introduction of vascular endothelial growth factor (VEGF) to angiogenesis, a critical process, actually occurs because of hypoxia – the absence of oxygen. Transcriptional factor HIF-1 (hypoxia inducible factor 1) allows this process to materialize. There is always a need for hypoxic tissue on tumors to promote the release of VEGF as they invariably aim to grow beyond the limits of the blood supply. Should we dedicate one chemotherapy treatment to block VEGF, we could then target ways to improve the tumor’s oxygen metabolism. Tumors cannot grow or spread without VEGF. By enhancing the body’s ability to carry oxygen and employing other cancer-killing methods simultaneously, Envita is creating new approaches to eliminate cancer and the processes that allow for their development and growth. One secret is the ability to create an environment that is unwelcome to stage 4 cancer cells. And there is more good news, now that we know that precarious blood cells are an excellent way to target cancers. Released VEGF binds to the endothelial cells of nearby vessels, and subsequently, they begin to break up and grow in the direction of the tumor in an effort to bring new vessels to feed it. These inferior vessels are relatively easy to detect through photodynamic protocols, which means they can be isolated and attacked while simultaneously strengthening healthy vessels throughout the body. Research shows that VEGF is connected with a series of tumor types, including breast, ovarian, cervical, esophageal, lung, and cervical cancer, as well as glioblastoma multiforme and renal cell carcinoma. It would seem that VEGF emissions may also hinder the immune system’s ability to react and fight off the tumor - regularly occurring in stage 4 cancers. One thing to keep in mind is that the immune system is the first and last defense against stage 4 cancer. More than 90 percent of all cancer patients die because of metastasis, a critical component for stage 4 cancer – the very process by which cancer cells can spread into the blood supply and be dispersed throughout the body. Sadly, many patients believe their cancer had been eradicated, only to discover later about dormant metastasis and why cancer comes back often at stage 4. For this reason, it is imperative to correct the body’s metabolism for oxygen and put a stop to angiogenesis.

For more information and articles on stage 4 cancer treatments, contact or visit us at Envita’s website. If you know anyone who has been diagnosed with cancer, please forward this article to them. We welcome you to contact us with questions and invite you to watch informative videos. You can also visit our PPMR section to learn more about the power of Envita’s personalized medicine (link to Envita PPMR page) for stage 4 cancer (link Envita cancer page) and chronic diseases. It is important information that may save lives. Education is the best prescription. Envita’s Comprehensive Smart Oncology uses the foremost of oncology in combination with aggressive natural therapies to help a patient reach better health.

References: *Judah Folkman < > , < > *Stage 4 Cancer < > * Vascular endothelial growth factor <>* <>*American Cancer Society < ment/acspc-029771.pdf>

Relevant Stage 4 Cancer Solutions